In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.
Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports identifying SARS-CoV-2 RDV resistance in patients, animal models or in vitro. Here, we selected drug-resistant viral populat...
Main Authors: | Agnieszka M Szemiel, Andres Merits, Richard J Orton, Oscar A MacLean, Rute Maria Pinto, Arthur Wickenhagen, Gauthier Lieber, Matthew L Turnbull, Sainan Wang, Wilhelm Furnon, Nicolas M Suarez, Daniel Mair, Ana da Silva Filipe, Brian J Willett, Sam J Wilson, Arvind H Patel, Emma C Thomson, Massimo Palmarini, Alain Kohl, Meredith E Stewart |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-09-01
|
Series: | PLoS Pathogens |
Online Access: | https://doi.org/10.1371/journal.ppat.1009929 |
Similar Items
-
The Timing and Magnitude of the Type I Interferon Response Are Correlated with Disease Tolerance in Arbovirus Infection
by: Alexandra Hardy, et al.
Published: (2023-06-01) -
Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection
by: Damiana-Maria Vulturar, et al.
Published: (2022-11-01) -
Chitosan-Based Nanocarriers for Delivery of Remdesivir
by: Viktoria Milkova, et al.
Published: (2023-08-01) -
Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19
by: Alireza FakhriRavari, et al.
Published: (2024-02-01) -
Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
by: Vasilis Petrakis, et al.
Published: (2022-09-01)